Elexxion AG has in the context of corporate action accepted new equity capital, rolled over the debt and equity relocated.
BCF has exclusively advised elexxion AG on the structuring and negotiation of the capital increase, the transfer of shares as well as the refinancing of shareholder loans. To finance further growth around 1.6 million shares were issued at par for subscription. Preliminary undertook the core investor to a drawing of EUR 1.3 million and a prolonging of its shareholder loan in the amount of EUR 700,000. The core investor has purchased a total of 2.4 million shares by management or its holding companies.
Founded in 2002, elexxion AG (www.elexxion.de) from Radolfzell is an innovative medical technology company that specializes in development, production and sales of dental laser systems. The products of elexxion are technologically advanced, protected by numerous patents and are characterized by an extremely user-friendly. As the world’s only company elexxion can currently offer with the product line delos a combination solution of high-power diode and Er: YAG lasers. At the annual new installations elexxion has a market share of around 25 percent in Germany. In the coming years, further promotion of sales in Europe and in the U.S. market is planned.
December 20, 2018
Quarton International advises evitria in its sale to AFINUM and SHS
To subscribe to our Newsletter, please use the following link.